RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
  • Load image into Gallery viewer, RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
  • Load image into Gallery viewer, RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
  • Load image into Gallery viewer, RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
  • Load image into Gallery viewer, RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
  • Load image into Gallery viewer, RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
  • Load image into Gallery viewer, RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)
  • Load image into Gallery viewer, RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)

RITUXAN/RUXIENCE/ TRUXIMA/RIABNI (Rituximab)

Vendor
ROCHE/PFIZER/CELLTRION/AMGEN
Regular price
$3,849.99 USD
Sale price
$3,849.99 USD
Regular price
Sold out
Unit price
per 
Shipping calculated at checkout.

prescription refrigerated

What is this medication?

RITUXAN/RUXIENCE/TRUXIMA/RIABNI (Rituximab)
Antineoplastic Agent; Antirheumatic Agent; Immunosuppressant Agent; Monoclonal Antibody

RITUXAN and biosimilars RUXIENCE, TRUXIMA, and RIABNI are CD20-directed cytolytic antibodies indicated for the treatment of Non-Hodgkin’s Lymphoma (NHL),  Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) in combination with methotrexate in moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies.

ALERT: WARNING
Rituximab administration can result in serious, including fatal, infusion-related reactions. Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion-related reactions occurred in association with the first infusion. Monitor patients closely. Discontinue rituximab infusion for severe reactions and provide medical treatment for grade 3 or 4 infusion-related reactions.  Fatal, mucocutaneous reactions can occur in patients receiving rituximab products.  Hepatitis B virus (HBV) reactivation can occur in patients treated with rituximab products, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with rituximab. Discontinue rituximab and concomitant medications in the event of HBV reactivation.  Progressive multifocal leukoencephalopathy (PML), including fatal PML, can occur in patients receiving rituximab products.

What is a biosimilar biologic drug?

Manufacturers have found cost-efficient ways to recreate the molecules used in the original or “reference” biologic drug.  Biosimilars are highly “similar” to a reference biological drug despite differing in their chemical composition.  

The FDA approval of biosimilar drugs is based on a totality of evidence which is used by regulators in the approval of reference and biological drugs.  The FDA uses the same approach in evaluating biosimilars to confirm that there are no clinically meaningful differences in safety and efficacy between the reference biologic drug and the biosimilar.  The rigorous standard for authorization means that you can have confidence knowing that the quality, safety, and efficacy of a biosimilar is the same as any other biologic drug.

RITUXAN is a biologic
RUXIENCE is a biosimilar to RITUXAN (Rituximab)
TRUXIMA is a biosimilar to RITUXAN (Rituximab)
RIABNI is a biosimilar to RITUXAN (Rituximab)

How does this medication work? 

Rituximab is a monoclonal antibody that kills CD20+ cells via multiple mechanisms.  The direct effects of rituximab include complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity, and the indirect effects include structural changes, apoptosis, and sensitization of cancer cells to chemotherapy. 

How should I take this medication? 

IV: Inject 375mg/m2 to 1000mg/m2 by intravenous infusion once weekly depending on indication.

How to Take: Must be administered in accordance with specific protocol rate guidelines by a trained medical professional.  To be administered intravenously only.  Do not administer IV push or bolus.  Do not administer IV rituximab, Rituxan subcutaneously. If an infusion-related reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate. Discontinue infusion in the event of serious or life-threatening cardiac arrhythmias.

What should I watch for while using this medication? 

Before starting make sure your physician is aware of any allergies or medications you currently take.  Hepatitis B reactivation with fulminant hepatitis can occur, discontinue Rituximab if reactivation occurs.  Cardiac arrhythmias and angina can occur and can be life threatening.  Bowel obstruction and perforation of the gastrointestinal tract has been reported, monitor for symptoms of abdominal pain.  Do not administer live virus vaccines prior to or during Rituximab. 

What if I miss a dose?

Contact your physician immediately if you miss a dose. Rituximab is administered at a doctor's office or infusion facility, you cannot take any missed doses at home on your own.

How should I store this medication?

Diluted solutions for infusion may be stored refrigerated at 2°C to 8°C (36°F to 46°F) for 24 hours. Diluted solutions for infusion have been shown to be stable for an additional 24 hours at room temperature.

Do not use beyond expiration date stamped on carton. Keep the vial in the outer carton to protect it from light.

What are the possible side effects of using this medication?

Cardiovascular effects including flushing, hypertension and edema; dermatologic effects including night sweats, itchiness, skin rash; gastrointestinal symptoms such as pain, nausea and diarrhea; urinary tract infection; hematologic changes such as neutropenia, anemia, lymphocytopenia; hepatic disorders/impairments such as hepatobiliary disease and elevated liver enzymes; antibody development; infection; join and muscle pain; respiratory symptoms such as cough, rhinitis and nasopharyngitis.

Note this is not a complete list of side effects for RITUXAN/RUXIENCE/TRUXIMA/RIABNI (Rituximab), only common ones.